Synapse

← Charles M. Perou

Papers by Charles M. Perou

Page 3 · newest first

  1. MRE11 liberates cGAS from nucleosome sequestration during tumorigenesisNature · 2024
  2. Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast CancerJAMA Network Open · 2023
  3. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy2023
  4. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trialsNature Communications · 2023
  5. Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerJournal of Clinical Investigation · 2023
  6. Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer2023
  7. Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast TumorsClinical Cancer Research · 2023
  8. Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJournal of Clinical Oncology · 2023
  9. Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)Clinical Cancer Research · 2023
  10. Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancerNature Communications · 2023
  11. Combination of Polymeric Micelle Formulation of TGFβ Receptor Inhibitors and Paclitaxel Produce Consistent Response Across Different Mouse Models of TNBC2023
  12. Gene-Expression Profiling to Decipher Breast Cancer Inter- and Intratumor HeterogeneityCold Spring Harbor Perspectives in Medicine · 2023
  13. Assessment of a Genomic Assay in Patients With ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without PertuzumabJAMA Oncology · 2023
  14. Assessment of the HER2DX Assay in Patients With ERBB2 -Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and PertuzumabJAMA Oncology · 2023
  15. Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysisESMO Open · 2023
  16. Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrencenpj Breast Cancer · 2023
  17. Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors2023
  18. Data from Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice2023
  19. Data from Activation of Host Wound Responses in Breast Cancer Microenvironment2023
  20. Data from Activation of Host Wound Responses in Breast Cancer Microenvironment2023
  21. Supplementary Data from A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer2023
  22. Supplementary Data from A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer2023
  23. Data from Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study2023
  24. CCR Translation for This Article from Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study2023
  25. Data from Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer2023
  26. Data from Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types2023
  27. Data from Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types2023
  28. Data from Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer2023
  29. Data from A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer2023
  30. Data from A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer2023
  31. Supplemental Figure 3 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics2023
  32. Data from Fibroblast Growth Factor Receptor Signaling Dramatically Accelerates Tumorigenesis and Enhances Oncoprotein Translation in the Mouse Mammary Tumor Virus–Wnt-1 Mouse Model of Breast Cancer2023
  33. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancerNature Communications · 2023
  34. Translating transcriptomic findings from cancer model systems to humans through joint dimension reductionCommunications Biology · 2023
  35. Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer RevealsTP53Aneuploidy–driven Metabolic ReprogrammingCancer Research Communications · 2023
  36. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast CancerJAMA Oncology · 2023
  37. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasisNature Cancer · 2022
  38. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1JNCI Journal of the National Cancer Institute · 2022
  39. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialEBioMedicine · 2022
  40. RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast CancerCancer Epidemiology Biomarkers & Prevention · 2022
  41. Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancerBreast Cancer Research and Treatment · 2022
  42. High-Dose Paclitaxel and its Combination with CSF1R Inhibitor in Polymeric Micelles for Chemoimmunotherapy of Triple Negative Breast Cancer2022
  43. Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS studynpj Breast Cancer · 2022
  44. Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of Recurrence2022
  45. Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based StudiesJNCI Journal of the National Cancer Institute · 2022
  46. Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer casesnpj Breast Cancer · 2022
  47. Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerClinical Cancer Research · 2022
  48. Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast CancerCancer Research · 2022
  49. The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer PatientsCancer Epidemiology Biomarkers & Prevention · 2022
  50. Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 womenScientific Reports · 2022